RT Journal Article
SR Electronic
T1 Admission systolic blood pressure and obesity correlate with fatal and severe acute COVID-19 in the population of New Orleans, LA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.27.24309604
DO 10.1101/2024.06.27.24309604
A1 Fusco, Dahlene
A1 Liu, Sharon
A1 Theberge, Marc
A1 Pulapaka, Anuhya V.
A1 Zha, Yitian
A1 Rittmeyer, William
A1 Maylin, Marlowe
A1 Rothwell, W. Ben
A1 Adhikari, Prateek
A1 Raynaud, Peter
A1 Ferdinand, Keith
A1 Drouin, Arnaud
YR 2024
UL http://medrxiv.org/content/early/2024/06/28/2024.06.27.24309604.abstract
AB BACKGROUND In New Orleans, Louisiana (NOLA), the population’s very high social vulnerability led to the establishment of an early epicenter for severe acute COVID-19. Anticipating future respiratory virus outbreaks, identifying low-cost correlates of outcome relevant to special populations is crucial.METHODS 89 patients with acute COVID-19, enrolled March to August 2020 in the ClinSeqSer longitudinal observational study.RESULTS The cohort’s population, ∼70% Black, 53% female and 55% obese, reflects exactly that of greater urban NOLA; In contrast, pre-COVID hypertension (HTN) is 83% and 1.5 to 2-fold the state’s prevalence (43% among White, 56% among Black residents). Black patients are younger than White (∼50% vs <= 30% in 45-64 years age bracket). Outcomes were 47% severe, including 17% fatal, and 30% non-fatal (high flow or intubated), and identical by race/age. Obesity, BMI, admit systolic blood pressure (SBP), pulse BP, and CRP level, but not race, sex, age, type 2 diabetes, HTN, number or specific anti-HTN drugs, correlated with fatal and severe outcomes. Patients with admission SBP ≥140 mmHg reached severe clinical state sooner than those with lower SBP.CONCLUSIONS The very high proportion of pre-COVID HTN in this acute COVID cohort correlates with high social vulnerability. Obesity and SBP on admission stand out as risks for fatal and severe outcomes of acute COVID. The findings support further study of acute COVID admit SBP as a potential correlate of outcome, and the potential role for interactions between a single strain of SARS CoV-2 and the renin-angiotensin-aldosterone blood pressure axis.Competing Interest StatementAD and DF have received investigator-initiated study awards from Gilead Sciences. AD and DF have served as site investigators for COVID-19 clinical trials sponsored by Gilead, Regeneron, and Metro Biotech LLC. DF has served on Advisory Boards for Gilead Sciences and AXCELLA.Clinical TrialNCT04956445Funding StatementFunding for this study was provided by Tulane University School of Medicine Start up packages (AD, DNF) and a Tulane University School of Medicine Deans Pilot Award (AD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was conducted with approval from Tulane University School of Medicine Institutional Review Board (IRB) under protocol Collection of SARS CoV-2 Serum and Secretions for Countermeasure Development [IRB 2020-396, approved 3/20/2020]. All procedures were performed in accordance with ethical standards of Tulane IRB and Helsinki Declaration of 1975 (revised 1983).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe presented data will be shared on reasonable request to the corresponding author.